Copyright Reports & Markets. All rights reserved.

Global Mucopolysaccharidosis (MPS) Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Mucopolysaccharidosis (MPS) Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Stem Cell Therapies
      • 1.4.3 Enzyme Replacement Therapies
    • 1.5 Market by Application
      • 1.5.1 Global Mucopolysaccharidosis (MPS) Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Homecare
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Mucopolysaccharidosis (MPS) Treatment Market Size
    • 2.2 Mucopolysaccharidosis (MPS) Treatment Growth Trends by Regions
      • 2.2.1 Mucopolysaccharidosis (MPS) Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Mucopolysaccharidosis (MPS) Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Mucopolysaccharidosis (MPS) Treatment Market Size by by Players
      • 3.1.1 Global Mucopolysaccharidosis (MPS) Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Mucopolysaccharidosis (MPS) Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Mucopolysaccharidosis (MPS) Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Mucopolysaccharidosis (MPS) Treatment Key Players Head office and Area Served
    • 3.3 Key Players Mucopolysaccharidosis (MPS) Treatment Product/Solution/Service
    • 3.4 Date of Enter into Mucopolysaccharidosis (MPS) Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Mucopolysaccharidosis (MPS) Treatment Market Size by Type (2014-2019)
    • 4.2 Global Mucopolysaccharidosis (MPS) Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 5.2 Mucopolysaccharidosis (MPS) Treatment Key Players in United States
    • 5.3 United States Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 5.4 United States Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 6.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Europe
    • 6.3 Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 6.4 Europe Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    7 China

    • 7.1 China Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 7.2 Mucopolysaccharidosis (MPS) Treatment Key Players in China
    • 7.3 China Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 7.4 China Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 8.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Japan
    • 8.3 Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 8.4 Japan Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 9.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 9.4 Southeast Asia Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    10 India

    • 10.1 India Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 10.2 Mucopolysaccharidosis (MPS) Treatment Key Players in India
    • 10.3 India Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 10.4 India Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size (2014-2019)
    • 11.2 Mucopolysaccharidosis (MPS) Treatment Key Players in Central & South America
    • 11.3 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Type
    • 11.4 Central & South America Mucopolysaccharidosis (MPS) Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Sanofi
      • 12.1.1 Sanofi Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.1.4 Sanofi Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.1.5 Sanofi Recent Development
    • 12.2 Shire (Takeda)
      • 12.2.1 Shire (Takeda) Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.2.4 Shire (Takeda) Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.2.5 Shire (Takeda) Recent Development
    • 12.3 BioMarin Pharmaceutical
      • 12.3.1 BioMarin Pharmaceutical Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.3.4 BioMarin Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.3.5 BioMarin Pharmaceutical Recent Development
    • 12.4 Esteve
      • 12.4.1 Esteve Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.4.4 Esteve Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.4.5 Esteve Recent Development
    • 12.5 REGENXBIO Inc
      • 12.5.1 REGENXBIO Inc Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.5.4 REGENXBIO Inc Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.5.5 REGENXBIO Inc Recent Development
    • 12.6 Sangamo Therapeutics
      • 12.6.1 Sangamo Therapeutics Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.6.4 Sangamo Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.6.5 Sangamo Therapeutics Recent Development
    • 12.7 Ultragenyx Pharmaceutical
      • 12.7.1 Ultragenyx Pharmaceutical Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.7.4 Ultragenyx Pharmaceutical Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.7.5 Ultragenyx Pharmaceutical Recent Development
    • 12.8 Abeona Therapeutics
      • 12.8.1 Abeona Therapeutics Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.8.4 Abeona Therapeutics Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.8.5 Abeona Therapeutics Recent Development
    • 12.9 ArmaGen
      • 12.9.1 ArmaGen Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.9.4 ArmaGen Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.9.5 ArmaGen Recent Development
    • 12.10 Eloxx Pharmaceuticals
      • 12.10.1 Eloxx Pharmaceuticals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Mucopolysaccharidosis (MPS) Treatment Introduction
      • 12.10.4 Eloxx Pharmaceuticals Revenue in Mucopolysaccharidosis (MPS) Treatment Business (2014-2019)
      • 12.10.5 Eloxx Pharmaceuticals Recent Development
    • 12.11 Inventiva

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules called glycosaminoglycans. These long chains of sugar carbohydrates occur within the cells that help build bone, cartilage, tendons, corneas, skin and connective tissue. Glycosaminoglycans (formerly called mucopolysaccharides) are also found in the fluids that lubricate joints.
      In 2018, the global Mucopolysaccharidosis (MPS) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Mucopolysaccharidosis (MPS) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Mucopolysaccharidosis (MPS) Treatment development in United States, Europe and China.

      The key players covered in this study
      Sanofi
      Shire (Takeda)
      BioMarin Pharmaceutical
      Esteve
      REGENXBIO Inc
      Sangamo Therapeutics
      Ultragenyx Pharmaceutical
      Abeona Therapeutics
      ArmaGen
      Eloxx Pharmaceuticals
      Inventiva

      Market segment by Type, the product can be split into
      Stem Cell Therapies
      Enzyme Replacement Therapies

      Market segment by Application, split into
      Hospitals
      Clinics
      Homecare

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Mucopolysaccharidosis (MPS) Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Mucopolysaccharidosis (MPS) Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Mucopolysaccharidosis (MPS) Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now